Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2017’, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS)

The report reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Human Immunodeficiency Virus (HIV) Infections (AIDS) therapeutics and enlists all their major and minor projects

The report assesses Human Immunodeficiency Virus (HIV) Infections (AIDS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Abivax SA

AdAlta Ltd

Advanced Genetic Systems Inc

Akshaya Bio Inc

Allergan Plc

Altor BioScience Corp

Altravax Inc

Amarna Therapeutics BV

American Gene Technologies International Inc

Amunix Operating Inc

Antigen Express Inc

Aphios Corp

ApoPharma Inc

Argos Therapeutics Inc

Arno Therapeutics Inc

Atreca Inc

B Cell Design SAS

Biological Mimetics Inc

Biotron Ltd

Boehringer Ingelheim GmbH

Bolder Biotechnology Inc

Bristol-Myers Squibb Company

Bukwang Pharm Co Ltd

C4X Discovery Holdings PLC

Calimmune Inc

Camurus AB

CEL-SCI Corp

Celgene Corp

Celldex Therapeutics Inc

Chipscreen Biosciences Ltd

Cocrystal Pharma Inc

CompleGen Inc

ConjuChem LLC

ContraVir Pharmaceuticals Inc

Critical Outcome Technologies Inc

Curevac AG

Cytodyn Inc

Dong-A Socio Holdings Co Ltd

Enzo Biochem Inc

EpiVax Inc

eTheRNA Immunotherapies NV

Etubics Corp

Excision BioTherapeutics Inc

FIT Biotech Oy

Fountain Biopharma Inc

Frontier Biotechnologies Co Ltd

Galmed Pharmaceuticals Ltd

GeneCure LLC

GeoVax Labs Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Globeimmune Inc

GW Pharmaceuticals Plc

H-Phar SA

Hadasit Medical Research Services & Development Ltd

Hanmi Pharmaceuticals Co Ltd

Heat Biologics Inc

iCo Therapeutics Inc.

ID Pharma Co Ltd

IGXBio Inc

Immune Response BioPharma Inc

Immune Therapeutics Inc

ImmunoClin Corp

Immunocore Ltd

Immunotope Inc

Immusoft Corp

ImQuest Life Sciences Inc

InnaVirVax SA

Innovative Targeting Solutions Inc

Inovio Pharmaceuticals Inc

Japan Tobacco Inc

Johnson & Johnson

Karyopharm Therapeutics Inc

KPI Therapeutics Inc

Kymab Ltd

Longevity Biotech Inc

MacroGenics Inc

Medestea Research & Production SpA

Medivir AB

Merck & Co Inc

Mologen AG

Mycenax Biotech Inc

Mymetics Corp

Myrexis Inc

NanoViricides Inc

Navigen Inc

NeED Pharma srl

New World Laboratories Inc

Novartis AG

Omeros Corp

Oncolys BioPharma Inc

Oncovir Inc

Orbis Biosciences Inc

Osel Inc

OyaGen Inc

PaxVax Inc

Peregrine Pharmaceuticals Inc

Pharis Biotec GmbH

Phoenix Biotechnology Inc

PlantForm Corp

Profectus BioSciences Inc

Recombio SL

Relmada Therapeutics Inc

Rodos BioTarget GmbH

Samjin Pharmaceutical Co Ltd

Sangamo Therapeutics Inc

Sanofi Pasteur SA

Sigma-Tau SpA

Sirenas Marine Discovery LLC

Solon Eiendom ASA

Spider Biotech

Spring Bank Pharmaceuticals Inc

Starpharma Holdings Ltd

Susavion Biosciences Inc

Taiga Biotechnologies Inc

TaiMed Biologics Inc

Takara Bio Inc

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

TeneoBio Inc

Theratechnologies Inc

Theravectys SA

Transgene Biotek Ltd

TVAX Biomedical Inc

United Biomedical Inc

Vaccibody AS

Vault Pharma Inc

VG Life Sciences Inc

Vichem Chemie Research Ltd

ViiV Healthcare Ltd

Viriom Inc

ViroStatics srl

XL-protein GmbH

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Overview 10

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Development 11

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment 53

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development 71

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drug Profiles 144

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects 829

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products 858

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones 862

Appendix 875

List of Tables

List of Tables

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..6), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by AbbVie Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Abivax SA, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by AdAlta Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Advanced Genetic Systems Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Akshaya Bio Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Allergan Plc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Altor BioScience Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Altravax Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Amarna Therapeutics BV, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by American Gene Technologies International Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Amunix Operating Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Antigen Express Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Aphios Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ApoPharma Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Argos Therapeutics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Arno Therapeutics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Atreca Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by B Cell Design SAS, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Biological Mimetics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Biotron Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Bolder Biotechnology Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Bristol-Myers Squibb Company, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Bukwang Pharm Co Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by C4X Discovery Holdings PLC, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Calimmune Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Camurus AB, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by CEL-SCI Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Celgene Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Celldex Therapeutics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Chipscreen Biosciences Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Cocrystal Pharma Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by CompleGen Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ConjuChem LLC, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Critical Outcome Technologies Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Curevac AG, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Cytodyn Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Enzo Biochem Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by EpiVax Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by eTheRNA Immunotherapies NV, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Etubics Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Excision BioTherapeutics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by FIT Biotech Oy, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Fountain Biopharma Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Frontier Biotechnologies Co Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Galmed Pharmaceuticals Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by GeneCure LLC, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by GeoVax Labs Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Gilead Sciences Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by GlaxoSmithKline Plc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Globeimmune Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by GW Pharmaceuticals Plc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by H-Phar SA, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Heat Biologics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by iCo Therapeutics Inc., H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ID Pharma Co Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by IGXBio Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Immune Response BioPharma Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Immune Therapeutics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ImmunoClin Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Immunocore Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Immunotope Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Immusoft Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ImQuest Life Sciences Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by InnaVirVax SA, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Innovative Targeting Solutions Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Japan Tobacco Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Johnson & Johnson, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by KPI Therapeutics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Kymab Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Longevity Biotech Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by MacroGenics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Medestea Research & Production SpA, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Medivir AB, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Merck & Co Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Mologen AG, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Mycenax Biotech Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Mymetics Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Myrexis Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by NanoViricides Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Navigen Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by NeED Pharma srl, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by New World Laboratories Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Novartis AG, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Omeros Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Oncolys BioPharma Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Oncovir Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Orbis Biosciences Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Osel Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by OyaGen Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by PaxVax Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Peregrine Pharmaceuticals Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Pharis Biotec GmbH, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Phoenix Biotechnology Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by PlantForm Corp, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Profectus BioSciences Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Recombio SL, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Relmada Therapeutics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Rodos BioTarget GmbH, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sangamo Therapeutics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sanofi Pasteur SA, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sigma-Tau SpA, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Sirenas Marine Discovery LLC, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Solon Eiendom ASA, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Spider Biotech, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Starpharma Holdings Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Susavion Biosciences Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Taiga Biotechnologies Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TaiMed Biologics Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Takara Bio Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TechnoVax Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TeneoBio Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Theratechnologies Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Theravectys SA, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Transgene Biotek Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by TVAX Biomedical Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by United Biomedical Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Vaccibody AS, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Vault Pharma Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by VG Life Sciences Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Vichem Chemie Research Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ViiV Healthcare Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Viriom Inc, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by ViroStatics srl, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by XL-protein GmbH, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..3), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..4), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..5), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..6), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..7), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..8), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..9), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..10), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..11), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..12), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..13), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..14), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..15), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..16), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..17), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..18), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..19), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..20), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..21), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..22), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..23), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..24), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2017 (Contd..25), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products, H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products, H1 2017 (Contd..1), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products, H1 2017 (Contd..2), H1 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures

List of Figures

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports